

Application No. 09/937,191

Filed: January 3, 2002

TC Art Unit: 1642

Confirmation No.: 6276

AMENDMENT TO THE CLAIMS

1. (Currently Amended) A method of using Utilization of at least one aminopeptidase inhibitor for the production of a medicament used in the treatment of very early stages of tumor diseases, the method comprising:

providing a subject suffering from or thought to be at risk of suffering from a tumor disease; and wherein the treated tumor is a primary tumor,

administering to the subject a medicament for treatment of a tumor disease, the medicament comprising an aminopeptidase inhibitor, whereby the at least one aminopeptidase inhibitor causes blocking of polarization of an invasive human or animal tumor cells cell by modifying at least one surface protein CD13, wherein the surface protein is as a member of a protein network on the surface of the invasive tumor cells cell, whereby the protein network comprises comprising up to 30 surface proteins selected from the group consisting of CD4, CD8, HLA-DR, HLA-DQ, CD3, CD26, CD38, CD45RA, CD16, CD57, CD56, CD7, CD54, CD58, CD138, CD13, CD62L, CD71, CD11b, CD36, CD29, CD49d, CD18, CD49f, CD19, CD2, CD20, CD10, CD44 and CD80

- |          |           |           |           |           |
|----------|-----------|-----------|-----------|-----------|
| 1. CD4   | 2. CD8    | 3. HLA DR | 4. HLA DQ | 5. CD3    |
| 6. CD26  | 7. CD38   | 8. CD45RA | 9. CD16   | 10. CD57  |
| 11. CD56 | 12. CD7   | 13. CD54  | 14. CD58  | 15. CD138 |
| 16. CD13 | 17. CD62L | 18. CD71  | 19. CD11b | 20. CD36  |
| 21. CD29 | 22. CD49d | 23. CD18  | 24. CD49f | 25. CD19  |
| 26. CD2  | 27. CD20  | 28. CD10  | 29. CD44  | 30. CD80. |

Application No. 09/937,191  
Filed: January 3, 2002  
TC Art Unit: 1642  
Confirmation No.: 6276

2. (Currently Amended) The ~~utilization as claimed in~~ method of claim 1, wherein characterized in that said at least one the aminopeptidase inhibitor is ~~an aminopeptidase inhibitor of the homophthalimide type~~ a homophthalimide, and/or an actinonin, and/or a bestatin, and/or an antibody, in particular a monoclonal antibody, against one of said surface proteins or a combination thereof.

3. (Canceled)

4. (Currently Amended) The ~~utilization as claimed in~~ method of claim 1, wherein characterized in that for producing said the medicament further comprises, an at least one additional inhibitor, the additional inhibitor inhibiting at least one member of the protein network, wherein the at least one member of the protein network is used that inhibits at least one surface protein that is not an aminopeptidase.

5. (Currently Amended) The ~~utilization as claimed in~~ method of claim 1, wherein characterized in that said at least one the aminopeptidase inhibitor ~~and/or at least one additional inhibitor~~ causes a modification of ~~at least one~~ a surface protein of the invasive said tumor cells cell, the which surface protein being is responsible for adhesion to an endothelial cells cell, and/or an extracellular structures structure, in particular organ-specific endothelial cells and/or organ specific extracellular structures or any combination thereof.

- 4 -

WEINMARTEN, SCHURCIN,  
CACHIERIN & LESOVICI LLP  
TEL. (817) 542-3290  
FAX. (617) 451-0313

**BEST AVAILABLE COPY**

Application No. 09/937,191

Filed: January 3, 2002

TC Art Unit: 1642

Confirmation No.: 6276

6. (Currently Amended) The ~~utilization as claimed in method of~~ claim ~~± 4, wherein characterized in that said at the least one~~ aminopeptidase inhibitor, ~~and/or at least one the~~ additional inhibitor ~~or a combination thereof will cause~~ causes modification of the ~~an -adhesive functions~~ function of at least one endothelial ~~cells~~ cell.

7. (Currently Amended) The ~~utilization as claimed method of in~~ claim ~~± 4, wherein characterized in that~~ the expression of ~~at least one a~~ surface protein, ~~in particular of an adhesion molecule, is~~ may be influenced by means of ~~at least one the~~ aminopeptidase inhibitor, ~~the and/or at least one~~ additional inhibitor ~~or a combination thereof~~.

8. (Canceled)

9. (Withdrawn) A method for identifying at least one aminopeptidase inhibitor that causes blocking of polarization of invasive human or animal tumor cells of a primary tumor created in the very early stages of tumor diseases, comprising:

a) detecting surface protein combinations of a protein network that are on the surface of the untreated tumor cells, whereby the protein network comprises up to 30 surface proteins selected from the group consisting of:

- |         |         |           |           |          |
|---------|---------|-----------|-----------|----------|
| 1. CD4  | 2. CD8  | 3. HLA-DR | 4. HLA-DQ | 5. CD3   |
| 6. CD26 | 7. CD38 | 8. CD45RA | 9. CD16   | 10. CD57 |

-5-

WEINGARTEN, SCHURGIN,  
CAHNERIN & LEDOVICI LLP  
TEL. (617) 542-2290  
FAX. (617) 451-0313

Application No. 09/937,191  
Filed: January 3, 2002  
TC Art Unit: 1642  
Confirmation No.: 6276

11. CD56	12. CD7	13. CD54	14. CD58	15. CD138
16. CD13	17. CD62L	18. CD71	19. CD11b	20. CD36
21. CD29	22. CD49d	23. CD18	24. CD49f	25. CD19
26. CD2	27. CD20	28. CD10	29. CD44	30. CD80;

b) treating said or similar tumor cells with at least one aminopeptidase inhibitor;

c) detecting said surface protein combinations of the protein network that are on the surface of the treated tumor cells; and

d) comparing the surface protein combinations detected in steps a) and c), whereby the at least one aminopeptidase inhibitor, if there is a divergence of the surface protein combinations detected in step a) from the surface protein combinations detected in step c) in that there is at least one modification of surface protein CD13, will cause blocking of polarization of said tumor cells.

10. (Withdrawn) The method as claimed in claim 9 characterized in that said method includes a further step, following step d), in which the at least one aminopeptidase inhibitor identified in step d) is added to at least one polarizing tumor cell and/or immune cell, and the further development of the at least one polarizing tumor cell and/or immune cell is detected.

11. (Withdrawn) The method as claimed in claim 9 characterized in that said method includes a further step, following step d), in which any binding of the untreated tumor cells to organ-specific endothelial cells and/or to organ-specific extracellular structures

Application No. 09/937,191  
Filed: January 3, 2002  
TC Art Unit: 1642  
Confirmation No.: 6276

is detected, in which any binding of the tumor cells treated with the at least one aminopeptidase inhibitor identified in step d) to the organ-specific endothelial cells and/or to the organ-specific extracellular structures is detected, and in which the detected bindings are compared.

12. (Withdrawn) A method for identifying at least one inhibitor that in combination with at least one aminopeptidase inhibitor, will cause blocking of polarization of invasive human or animal tumor cells of a primary tumor created in the very early stages of tumor diseases, comprising:

a) detecting surface protein combinations of a protein network that are on the surface of the untreated tumor cells, whereby the protein network comprises up to 30 surface proteins selected from the group consisting of:

- |          |           |           |           |           |
|----------|-----------|-----------|-----------|-----------|
| 1. CD4   | 2. CD8    | 3. HLA-DR | 4. HLA-DQ | 5. CD3    |
| 6. CD26  | 7. CD38   | 8. CD45RA | 9. CD16   | 10. CD57  |
| 11. CD56 | 12. CD7   | 13. CD54  | 14. CD58  | 15. CD138 |
| 16. CD13 | 17. CD62L | 18. CD71  | 19. CD11b | 20. CD36  |
| 21. CD29 | 22. CD49d | 23. CD18  | 24. CD49f | 25. CD19  |
| 26. CD2  | 27. CD20  | 28. CD10  | 29. CD44  | 30. CD80; |

b) treating said or similar tumor cells with at least one potential inhibitor that is not directed against an aminopeptidase;

c) detecting the surface protein combinations of the protein network that are on the surface of the treated tumor cells; and

d) comparing the surface protein combinations detected in steps a) and c), whereby the at least one inhibitor, if there is a

-7-

WEINGARTEN, SCHUEGIN,  
GARTENIN & LEBOVICI LLP  
TEL. (617) 542-2090  
FAX. (617) 451-0313

Application No. 09/937,191

Filed: January 3, 2002

TC Art Unit: 1642

Confirmation No.: 6276

divergence of the surface protein combinations detected in step a) from the surface protein combinations detected in step c) in that there is at least one modification of a surface protein, will be suitable for blocking polarization of said tumor cells.

13. (Withdrawn) The method as claimed in claim 12 characterized in that said or similar tumor cells are also treated with at least one aminopeptidase inhibitor in step b), with the combination of the at least one inhibitor and the at least one aminopeptidase inhibitor, if there is a divergence of the surface protein combinations detected in step a) from the surface protein combinations detected in step c) in that there is at least one modification of a surface protein CD13, will cause blocking of polarization of the tumor cells and/or immune cells.

14. (Withdrawn) The method as claimed in claim 12 characterized in that said method includes a further step, following step d), in which the at least one aminopeptidase inhibitor identified in step d) or a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor is added to at least one polarizing tumor cell and/or immune cell, and the further development of the at least one polarizing tumor cell and/or immune cell is detected.

15. (Withdrawn) The method as claimed in claim 12 characterized in that said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells

- 8 -

WEINGARTEN, SCHUBERT,  
GAGNON & LEBOVITZ LLP  
TEL. (617) 542-2290  
FAX. (617) 431-0313

Application No. 09/937,191

Filed: January 3, 2002

TC Art Unit: 1642

Confirmation No.: 6276

to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one inhibitor identified in step d) or with a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor to the organ-specific endothelial cells and/or to the organ-specific extracellular structures is detected, and in which the detected bindings are compared.

16. (Canceled)

17. (Withdrawn) The method as claimed in claim 10 characterized in that said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one aminopeptidase inhibitor identified in step d) to the organ-specific endothelial cells and/or to the organ-specific extracellular structures is detected, and in which the detected bindings are compared.

18. (Withdrawn) The method as claimed in claim 13 characterized in that said method includes a further step, following step d), in which the at least one aminopeptidase inhibitor identified in step d) or a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor is added to at

- 9 -

WEINSTEIN, SCHULZIN,  
GAGNEBIN & LEBOVICI LLP  
TEL. (617) 542-2290  
FAX. (617) 451-0313

Application No. 09/937,191

Filed: January 3, 2002

TC Art Unit: 1642

Confirmation No.: 6276

least one polarizing tumor cell and/or immune cell, and the further development of the at least one polarizing tumor cell and/or immune cell is detected.

19. (Withdrawn) The method as claimed in claim 13 characterized in that said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one inhibitor identified in step d) or with a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor to the organ-specific endothelial cells and/or to the organ-specific extracellular structures is detected, and in which the detected bindings are compared.

20. (Withdrawn) The method as claimed in claim 14 characterized in that said method includes a further step, following step d), in which any binding of the untreated tumor cells and/or immune cells to organ-specific endothelial cells and/or to organ-specific extracellular structures is detected, in which any binding of the tumor cells and/or immune cells treated with the at least one inhibitor identified in step d) or with a combination of the at least one inhibitor identified in step d) and at least one aminopeptidase inhibitor to the organ-specific endothelial cells and/or to the organ-specific extracellular structures is detected, and in which the detected bindings are compared.

-10-

WEINGARTEN, SCHEUROW,  
GARDNER & LEBOWITZ LLP  
TEL. (617) 542-2290  
FAX. (617) 451-0313



Application No. 09/937,191

Filed: January 3, 2002

TC Art Unit: 1642

Confirmation No.: 6276

21. (Currently Amended) A pharmaceutical preparation for treatment of tumor diseases ~~which can be produced using at least one aminopeptidase inhibitor or a combination of at least one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claim 2,~~ the preparation comprising:

an aminopeptidase inhibitor, wherein the inhibitor causes blocking of polarization of an invasive tumor cell by modifying at least one surface protein, wherein the surface protein is a member of a protein network on the surface of the invasive tumor cell, the protein network comprising proteins selected from the group consisting of CD4, CD8, HLA-DR, HLA-DQ, CD3, CD26, CD38, CD45RA, CD16, CD57, CD56, CD7, CD54, CD58, CD138, CD13, CD62L, CD71, CD11b, CD36, CD29, CD49d, CD18, CD49f, CD19, CD2, CD20, CD10, CD44 and CD80.

22. (Canceled)

23. (Currently Amended) ~~A The pharmaceutical preparation of claim 21, the preparation further comprising an additional inhibitor which can be produced using at least one aminopeptidase inhibitor or a combination of at least one aminopeptidase inhibitor and at least one additional inhibitor as claimed in claim 4.~~

24. (Currently Amended) ~~A The pharmaceutical preparation of claim 23, wherein the which can be produced using at least one aminopeptidase inhibitor or a combination of at least one~~

-11-

WEINCARTER, SCHURGIN,  
GACHESIN & LEBOVICI LLP  
TEL. (617) 542-2290  
FAX. (617) 451-0313

Application No. 09/937,191  
Filed: January 3, 2002  
TC Art Unit: 1642  
Confirmation No.: 6276

~~aminopeptidase inhibitor and at least one additional inhibitor as~~  
~~claimed in claim 5 causes blocking of polarization of an invasive~~  
~~tumor cell by modifying at least one surface protein that is not~~  
~~an aminopeptidase, wherein the surface protein is a member of a~~  
~~protein network on the surface of the invasive tumor cell, the~~  
~~protein network comprising proteins selected from the group~~  
~~consisting of CD4, CD8, HLA-DR, HLA-DQ, CD3, CD26, CD38, CD45RA,~~  
~~CD16, CD57, CD56, CD7, CD54, CD58, CD138, CD13, CD62L, CD71,~~  
~~CD11b, CD36, CD29, CD49d, CD18, CD49f, CD19, CD2, CD20, CD10, CD44~~  
~~and CD80.~~

25. (Canceled)

26. (Canceled)

27. (New) The method of claim 4, wherein the additional inhibitor causes a modification of a surface protein of the invasive tumor cell, the surface protein being responsible for adhesion to an endothelial cell, an extracellular structure or any combination thereof.

28. (New) The method of claim 4, wherein the additional inhibitor is a homophthalimide, a actinonin, a bestatin, an antibody against one of said surface proteins or a combination thereof.

29. (New) The method of claim 1, wherein the at least one surface protein is CD13.

-12-

WEINGARTEN, SCHURGIN,  
GAGNERIN & LEPOVICKI LLP  
TEL. (617) 542-2290  
FAX. (617) 451-0313

Application No. 09/937,191  
Filed: January 3, 2002  
TC Art Unit: 1642  
Confirmation No.: 6276

30. (New) The pharmaceutical preparation of claim 21, wherein the at least one surface protein is CD13.

- 13 -

WEINBERG, SCHUGIN,  
CAGNINI & LEONOVICI LLP  
TEL. (617) 542-2200  
FAX. (617) 451-0313

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**